EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Optimal Dosage Justification for Datopotamab Deruxtecan in HR ‐Positive/ HER2 ‐Negative Breast Cancer Through Model‐Informed Drug Development Approaches

Zoey Tang iD, KyoungSoo Lim iD, Yu Jiang, David Dai, Manjunatha Munegowda iD, Sabrina Khan iD, Lu Xu, Lei Shi, Yuzhuo Pan, Ying Hong, Song Ren, Pavan Vajjah und 2 weitere

Clinical and Translational Science · 2026-02 · 19 (2)

DOI: 10.1111/cts.70493 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 15.02.2026. Verfasst von Zoey Tang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Gaithersburg, Maryland, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Development, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Project Optimus has been reforming the dose selection and optimization paradigm in oncology. In this context, model‐informed drug development (MIDD) approaches were utilized to validate the optimal dose selection of 6 mg/kg every 3 weeks (Q3W) for datopotamab deruxtecan (Dato‐DXd) in patients with HR‐positive/HER2‐negative breast cancer (HR+/HER2− BC). A Tumor Growth Inhibition (TGI)–Progression‐Free Survival (PFS) modeling framework was developed to assess the relationship between Dato‐DXd PK exposure, tumor dynamics, and PFS, and support virtual trial simulations at different Dato‐DXd dose levels. Simulations suggested that Dato‐DXd at 6 mg/kg Q3W provide superior tumor control and improved PFS compared to a lower dose in patients with HR+/HER2− BC. This work underscores the importance of integrating advanced modeling techniques into the dose optimization paradigm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsDrug DevelopmentAntibodies, Monoclonal, HumanizedHumansFemaleErb-b2 Receptor Tyrosine KinasesModels, BiologicalProgression-Free SurvivalDose-Response Relationship, DrugComputer Simulation

Stichwörter der Autor:innen

ADCDato‐DXdHR+/HER2− breast cancerTROP2

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Gaithersburg, Maryland, USA.
  • Clinical Development, Oncology R&D, Mississauga, Ontario, Canada.
  • Clinical Development, Oncology R&D, Gaithersburg, Maryland, USA.
  • Statistics, Oncology R&D, New York, New York, USA.
  • Statistics, Oncology R&D, Gaithersburg, Maryland, USA.
  • Quantitative Clinical Pharmacology, Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA.

ORCID-Profile: Zoey Tang, KyoungSoo Lim, Manjunatha Munegowda, Sabrina Khan, Diansong Zhou

Zitieren

APA

Tang, Z., Lim, K., Jiang, Y., Dai, D., Munegowda, M., Khan, S., Xu, L., Shi, L., Pan, Y., Hong, Y., Ren, S., Vajjah, P., Gibbs, M., & Zhou, D. (2026). Optimal Dosage Justification for Datopotamab Deruxtecan in HR ‐Positive/ HER2 ‐Negative Breast Cancer Through Model‐Informed Drug Development Approaches. Clinical and Translational Science, 19(2). https://doi.org/10.1111/cts.70493

Vancouver

Tang Z, Lim K, Jiang Y, Dai D, Munegowda M, Khan S, et al. Optimal Dosage Justification for Datopotamab Deruxtecan in HR ‐Positive/ HER2 ‐Negative Breast Cancer Through Model‐Informed Drug Development Approaches. Clinical and Translational Science. 2026;19(2). doi:10.1111/cts.70493

BibTeX
@article{Tang2026,
  author = {Tang, Zoey and Lim, KyoungSoo and Jiang, Yu and Dai, David and Munegowda, Manjunatha and Khan, Sabrina and Xu, Lu and Shi, Lei and Pan, Yuzhuo and Hong, Ying and Ren, Song and Vajjah, Pavan and Gibbs, Megan and Zhou, Diansong},
  title = {Optimal Dosage Justification for Datopotamab Deruxtecan in HR ‐Positive/ HER2 ‐Negative Breast Cancer Through Model‐Informed Drug Development Approaches},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {2},
  doi = {10.1111/cts.70493}
}
Kostenlos starten →